Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224354 | 0.79 | ALDH1A1 (0.53) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL22326459 | 0.79 | KDM1A (0.46) | ADH1BADH1CADH1AADH7MAPK1 | |
| SCHEMBL21354949 | 0.79 | ADH1B (0.37) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL657873 | 0.79 | ADH1B (0.41) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL1514918 | 0.77 | NFE2L2 (0.39) | ALDH1A1NFE2L2HTTSMN1; SMN2GAA | |
| SCHEMBL1338097 | 0.76 | NFE2L2 (0.36) | ALDH1A1HPGDNFE2L2HTTSMN1; SMN2 | |
| SCHEMBL21355297 | 0.76 | ADH1B (0.35) | ADH1BADH1CADH1AADH7KMT2A | |
| SCHEMBL29724046 | 0.76 | KLKB1 (0.35) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL21355260 | 0.76 | KLKB1 (0.35) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL1128728 | 0.76 | ADH1B (0.36) | ADH1BADH1CADH1AADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | ADH1B 3730/4885ADH1C 3527/4885ADH1A 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.